866-997-4948(US-Canada Toll Free)

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 58 Pages

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016, provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
- The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview 7
Therapeutics Development 8
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Stage of Development 8
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Therapy Area 9
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Indication 10
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Products Glance 12
Early Stage Products 12
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Companies 13
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Universities/Institutes 16
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Companies Involved in Therapeutics Development 24
Amgen Inc. 24
Axxam SpA 25
Bionomics Limited 26
conoGenetix biosciences GmbH 27
Johnson & Johnson 28
KPI Therapeutics, Inc. 29
Sevion Therapeutics, Inc. 30
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drug Profiles 31
BNC-164 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
cgtx-A - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
cgtx-F - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
cgtx-G - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
dalazatide - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
KPI-150 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
KPI-190 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
OSK-1 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
SVN-001 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Dormant Projects 48
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Featured News & Press Releases 50
Jun 20, 2016: Dalazatide as a Potential Immunotherapy for Lupus to be Presented at Immunology Conference 50
Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus 50
May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus 51
May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference 51
Apr 18, 2016: KPI Therapeutics to Present Dalazatide Plaque Psoriasis Data at Dermatology Conference 51
Mar 21, 2016: KPI Therapeutics Presents Promising Data on KPI-190 as Potential Therapy for Uveitis, Autoimmune Eye Diseases 52
Mar 14, 2016: KPI Therapeutics to Present Dalazatide Data as Potential Therapy for Uveitis, Autoimmune Eye Diseases at Ocular Conference 52
Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases 52
Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases 53
Feb 03, 2016: KPI Invited to Present at BIO CEO & Investor in NYC 53
Nov 10, 2015: Kineta, Seattle Childrens Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 54
Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting 54
Sep 21, 2015: Kineta Chief Scientist to Speak on Dalazatide Clinical Results, Potential Therapy for Autoimmune Diseases at Basel Life Science Week 55
Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation 55
Jul 08, 2015: Kineta Chief Scientist Invited to Speak on Dalazatide Phase 1 B Clinical Trial 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Amgen Inc., H2 2016 24
Pipeline by Axxam SpA, H2 2016 25
Pipeline by Bionomics Limited, H2 2016 26
Pipeline by conoGenetix biosciences GmbH, H2 2016 27
Pipeline by Johnson & Johnson, H2 2016 28
Pipeline by KPI Therapeutics, Inc., H2 2016 29
Pipeline by Sevion Therapeutics, Inc., H2 2016 30
Dormant Projects, H2 2016 48
Dormant Projects (Contd..1), H2 2016 49

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *